Patients with schizophrenia have increased mortality and morbidity compared with the
general population. These patients have a 20-year shorter lifespan than peers without …

This paper presents the 12th update of the human obesity gene map, which incorporates
published results up to the end of October 2005. Evidence from single‐gene mutation …

Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease
and type II diabetes, are significant problems for patients receiving antipsychotic drugs and …

Atypical antipsychotic drugs offer several notable benefits over typical antipsychotics,
including greater improvement in negative symptoms, cognitive function, prevention of …

Atypical antipsychotics have greatly enhanced the treatment of schizophrenia. The
mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not …

Although weight gain is a serious but variable adverse effect of antipsychotics that has
genetic underpinnings, a comprehensive meta-analysis of pharmacogenetics of …

Up to 30% of people with schizophrenia do not respond to two (or more) trials of
dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS) …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

The last decade of research into the pharmacogenetics of antipsychotics has seen the
development of genetic tests to determine the patients' metabolic status and the first attempts …

Importance of the field: Antipsychotic drug is the mainstay of treatment for schizophrenia,
and there are large inter-individual differences in clinical response and side effects …